Nick Tribble

Nick has 10 years of pre-clinical experience from his time at Adaptimmune. There, he led the charge in early pipeline TCR discovery and guided his team in developing the company's flagship clinical TCR.

Prior to joining Cancer Research Horizons in August 2024, Nick was a senior programme manager at Lonza, where he was responsible for the delivery of multiple projects focused on delivering improved antibody manufacturing processes.

Nick gained his PhD in molecular pharmacology from the Atlantic Veterinary College, Canada, and conducted post-doctoral studies on monogenic diabetes at the University of Oxford.